Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Chang Gung University is managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct examiners and 3 distinct art units. This perfect distribution across art units suggests that each pending application represents a different specialized field of biotechnology.
JONES, CHRISTINE MICHELLE is the busiest examiner with 1 pending action. Because each case is in a different art unit, the university must adapt to 3 entirely different sets of examination standards and technical expertise. This decentralized structure requires a versatile prosecution strategy that can handle the specific nuances of 3 distinct examiners. The involvement of 3 distinct art units highlights the breadth of the university's pharmaceutical research. Success in these matters will depend on the ability to address the unique prior art and legal hurdles present in each specialized group. No single examiner has a dominant influence over the portfolio, which provides a level of protection against individual examiner bias.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §102 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES, CHRISTINE MICHELLE | 1 | 0.0% | +0.0% |
| LIEB, JEANETTE M | 1 | 79.9% | +17.2% |
| JAVANMARD, SAHAR | 1 | 64.8% | +34.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18617874 | NUCLEIC ACID AMPLIFICATION METHOD AND DEVICE, AND NUCLEIC ACID DETECTION METHOD AND DEVICE | JONES, CHRISTINE MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18219105 | METHODS FOR EXTENDING LIFESPAN AND/OR DELAYING AGING | JAVANMARD, SAHAR | 1d overdue |
| 18499169 | OPHTHALMIC DRUG DELIVERY CARRIER AND METHOD FOR PREPARING THE SAME | LIEB, JEANETTE M | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1654 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18617874 | NUCLEIC ACID AMPLIFICATION METHOD AND DEVICE, AND NUCLEIC ACID DETECTION METHOD AND DEVICE | JONES, CHRISTINE MICHELLE | 1682 | §102§103§112 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18499169 | OPHTHALMIC DRUG DELIVERY CARRIER AND METHOD FOR PREPARING THE SAME | LIEB, JEANETTE M | 1654 | §102 | Non-Final OA | — | Pending | Oct 31, 2023 |
| 18219105 | METHODS FOR EXTENDING LIFESPAN AND/OR DELAYING AGING | JAVANMARD, SAHAR | 1622 | §103 | Non-Final OA | 1d overdue | Pending | Jul 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial